---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000089"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:50:20.024127+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive

## Summary
- Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).
- Net income $0.7M vs loss of $11.5M in Q2 2023; generated $15.8M free cash flow.
- Narrows 2024 net product revenue guidance to $210-220M from $200-220M.
- 2,336 patients on LUPKYNIS (+22% YoY); AUR200 Phase 1 SAD starts Q3 2024.
- Cash $330.7M; repurchased 3.4M shares for $18.6M YTD.

## SEC filing metadata
- accession: 0001600620-24-000089
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/0001600620-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/auph-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000089
- JSON: https://secwatch.observer/filing/0001600620-24-000089.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.